Warren Alpert Foundation Prize

Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine

Retrieved on: 
Wednesday, December 6, 2023
Woman, Associate, Trastuzumab, FACP, Radiation, Therapy, National Cancer Institute, Emory University, Conference call, Breast cancer, NCI, Cleveland Clinic, Medicine, McGill University, FRCPC, MBBS, Conference, Harvard Medical School, Cancer, Outline of health sciences, Immunotherapy, Minda, Warren Alpert Foundation Prize, Communications satellite, Pharmaceutical industry, MD, Paclitaxel

SAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, will publicly release new data this evening from the ongoing Phase 1 clinical trial of its breast cancer vaccine, which was presented for the first time today at the 2023 San Antonio Breast Cancer Symposium ("SABCS"). All interested parties are invited to join an upcoming conference call today at 6:30 pm ET to discuss the data.

Key Points: 
  • All interested parties are invited to join an upcoming conference call today at 6:30 pm ET to discuss the data.
  • Anixa is pleased to invite all interested parties to participate in a conference call today at 6:30 p.m.
  • Jennifer Davis: Ms. Davis is a nurse, wife, mother of three, and Triple Negative Breast Cancer survivor.
  • Dr. Shepard is best known as the inventor of the life-saving breast cancer drug Herceptin® (trastuzumab).

IFF’s Philippe Horvath Inducted into The National Inventors Hall of Fame

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Health, Specialty, Food, Beverage, Other Science, Cosmetics, Research, Infectious Diseases, Retail, Genetics, Science, All rights reserved, Degenerative disease, National Inventors Hall of Fame, Virus, Trademark, NYSE, Health, Franklin Institute Awards, Bacteria, Gene editing, International Flavors & Fragrances, Rodolphe Barrangou, Immune system, Creativity, Research, Massry Prize, North East of England Process Industry Cluster, Warren Alpert Foundation Prize, Canada Gairdner International Award, Horváth, Food, Vaccine, Perfume, CRISPR, D.C, Science

Philippe Horvath—renowned molecular biologist and IFF technical fellow—is being inducted into the National Inventors Hall of Fame® Class of 2023.

Key Points: 
  • Philippe Horvath—renowned molecular biologist and IFF technical fellow—is being inducted into the National Inventors Hall of Fame® Class of 2023.
  • Applying this research to enhance starter cultures in the dairy industry, Horvath and research partner Rodolphe Barrangou improved the world’s food supply and laid the foundation for the field of gene editing.
  • “We are proud of the achievements made by Philippe and the entire CRISPR team.
  • “I am deeply honored to be selected by the National Inventors Hall of Fame to represent the pioneering work our team has done,” said Horvath.

ReviR Therapeutics Announces Addition of Dr. Lynne E. Maquat and Dr. Brian Safina to Scientific Advisory Board

Retrieved on: 
Friday, May 13, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Senior, RNA transfection, American Academy, Immunology, Research, John J. Carty Award for the Advancement of Science, Voyager, Disease, National, University of Rochester, The arts, Wolf Prize, Biochemistry, Warren Alpert Foundation Prize, EJC, NMD, Association, Therapy, RNA Society, National Academy of Medicine, National academy, Biophysics, Patent, Wolf Prize in Medicine, Fellow of the American Association for the Advancement of Science, RNA, Genentech, University, MicroRNA, American Association, United States Air Force Scientific Advisory Board, Harvard Medical School, University of California, San Diego, Entrepreneurship, Neuroscience, Drug discovery, Pharmaceutical industry, Medical device, Medicine, Science, Science

ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced today the formation and members of its Scientific Advisory Board with the appointments of Dr. Lynne E. Maquat and Dr. Brian Safina.

Key Points: 
  • ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced today the formation and members of its Scientific Advisory Board with the appointments of Dr. Lynne E. Maquat and Dr. Brian Safina.
  • We are honored to welcome Dr. Maquat and Dr. Safina to our Scientific Advisory Board, said Peng Yue, Ph.D., Co-Founder, and Chief Executive Officer of ReviR Therapeutics.
  • Each expert will bring in-depth knowledge of RNA biology as well as drug discovery and development expertise.
  • Dr. Maquat brings to ReviR decades of experience in RNA research.

2020 Szent-Györgyi Prize Awarded to a Pioneering Researcher Who Has Unlocked Workings of Cancer Drugs of Natural Product Origin

Retrieved on: 
Thursday, February 13, 2020
Organic compounds, Carbonyl compounds, Oxygen compounds, National Foundation for Cancer Research, Horwitz, Paclitaxel, Szent-Györgyi Prize for Progress in Cancer Research, Warren Alpert Foundation Prize

The Prize selection committee awarded Dr. Horwitz for pioneering the understanding, at the molecular level, of the mechanisms of action and resistance of multiple effective and widely utilized anti-tumor drugs, particularly Taxol, of natural product origin.

Key Points: 
  • The Prize selection committee awarded Dr. Horwitz for pioneering the understanding, at the molecular level, of the mechanisms of action and resistance of multiple effective and widely utilized anti-tumor drugs, particularly Taxol, of natural product origin.
  • "We are so proud that Dr. Horwitz becomes the third National Foundation for Cancer Research supported scientist to be awarded the Szent-Gyrgyi Prize, after Dr.
  • "I am deeply honored by this award from the National Foundation for Cancer Research and the Szent-Gyrgyi Prize selection committee," stated Dr. Horwitz.
  • "It is a real privilege to be among the winners of this prize, all of whom have greatly advanced cancer research and treatment.